Literature DB >> 12079215

A rational approach to the follow-up of melanoma patients.

Claus Garbe1.   

Abstract

There are no generally accepted guidelines for the follow-up of cutaneous melanoma (CM), and there is an ongoing debate about the value of follow-up examinations. Some authors doubt whether early detection has any beneficial effect on patient survival and suggest that it may only prolong the patient's period of suffering from the knowledge of having metastasis. A systematic review of the literature on early detection and resection of CM metastasis shows the following picture: (1) In in-transit metastasis and in regional node metastasis, the tumour volume of the metastatic nodules at the time of diagnosis is prognostically significant. Either the number of nodes involved in regional metastasis or the diameter of the largest node showed prognostic impact in different studies. Therefore, early detection seems to affect the cure rate in this stage of disease. (2) In distant metastasis, surgical resection of all recognisable metastases prolongs survival. This is true as long as only one organ system is involved and particularly if complete resection of all metastases can be achieved. Therefore, early detection contributes to prolongation of survival. We performed a follow-up study in 2008 prospectively documented consecutive patients with stage I-III cutaneous melanoma who presented for follow-up examination at the Department of Dermatology of the University of Tübingen from August 1996 to August 1998. Stage-appropriate follow-up examinations were carried out according to the German Society of Dermatology guidelines. A total of 3,800 clinical examinations and 12,398 imaging techniques were documented: 62 second primary melanomas were detected in 46 patients and 233 disease recurrences in 112 patients during this time. Physical examination was responsible for the discovery of 50% of all recurrences, with the patient initially detecting the metastasis on self-examination in 17% of these cases. Technical examinations were responsible for the detection of the remaining 50%. In the primary tumour stages, 21% of all recurrences were discovered by lymph node sonography, the majority being classified as early detection. Among the recurrences, 48% were classified as early detection, and these patients had a significantly more favourable probability of recurrence-free survival than those with recurrences classified as late detection. The results of our study suggest that a follow-up schedule elaborated for cutaneous melanoma is suitable for the early detection of second primary melanomas and of early recurrences in approximately 5% of patients during a 2-year follow-up period.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12079215     DOI: 10.1007/978-3-642-59410-6_24

Source DB:  PubMed          Journal:  Recent Results Cancer Res        ISSN: 0080-0015


  5 in total

Review 1.  Long-term follow-up for melanoma patients: is there any evidence of a benefit?

Authors:  Natasha M Rueth; Kate D Cromwell; Janice N Cormier
Journal:  Surg Oncol Clin N Am       Date:  2015-01-24       Impact factor: 3.495

Review 2.  Variability in melanoma post-treatment surveillance practices by country and physician specialty: a systematic review.

Authors:  Kate D Cromwell; Merrick I Ross; Yan Xing; Jeffrey E Gershenwald; Richard E Royal; Anthony Lucci; Jeffrey E Lee; Janice N Cormier
Journal:  Melanoma Res       Date:  2012-10       Impact factor: 3.599

3.  Melanoma survivorship: research opportunities.

Authors:  Susan A Oliveria; Jennifer L Hay; Alan C Geller; Maureen K Heneghan; Mary S McCabe; Allan C Halpern
Journal:  J Cancer Surviv       Date:  2007-03       Impact factor: 4.442

4.  Prognosis of sentinel node staged patients with primary cutaneous melanoma.

Authors:  Otmar Elsaesser; Ulrike Leiter; Petra G Buettner; Thomas K Eigentler; Friedegund Meier; Benjamin Weide; Gisela Metzler; Helmut Breuninger; Claus Garbe
Journal:  PLoS One       Date:  2012-01-19       Impact factor: 3.240

5.  Serum microRNAs as biomarkers for recurrence in melanoma.

Authors:  Erica B Friedman; Shulian Shang; Eleazar Vega-Saenz de Miera; Jacob Ulrik Fog; Maria Wrang Teilum; Michelle W Ma; Russell S Berman; Richard L Shapiro; Anna C Pavlick; Eva Hernando; Adam Baker; Yongzhao Shao; Iman Osman
Journal:  J Transl Med       Date:  2012-08-02       Impact factor: 5.531

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.